NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.52 -0.04 (-0.88 %)
(As of 11/18/2018 04:00 PM ET)
Previous Close$4.52
Today's Range$4.45 - $4.66
52-Week Range$3.34 - $12.45
Volume23,570 shs
Average Volume208,832 shs
Market Capitalization$60.31 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56
Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MACK
Previous Symbol
CUSIP59032810
Phone617-441-1000

Debt

Debt-to-Equity Ratio0.22
Current Ratio3.96
Quick Ratio3.96

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$144.27 million
Price / Sales0.42
Cash FlowN/A
Price / CashN/A
Book Value$5.02 per share
Price / Book0.90

Profitability

EPS (Most Recent Fiscal Year)($5.66)
Net Income$472.02 million
Net MarginsN/A
Return on Equity-78.33%
Return on Assets-59.85%

Miscellaneous

Employees72
Outstanding Shares13,340,000
Market Cap$60.31 million
OptionableOptionable

Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Merrimack Pharmaceuticals shares reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) posted its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.65. View Merrimack Pharmaceuticals' Earnings History.

When is Merrimack Pharmaceuticals' next earnings date?

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Merrimack Pharmaceuticals.

What price target have analysts set for MACK?

3 brokers have issued 12-month price targets for Merrimack Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they expect Merrimack Pharmaceuticals' share price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 11.5%. View Analyst Price Targets for Merrimack Pharmaceuticals.

What is the consensus analysts' recommendation for Merrimack Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merrimack Pharmaceuticals in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merrimack Pharmaceuticals.

Has Merrimack Pharmaceuticals been receiving favorable news coverage?

News coverage about MACK stock has trended very positive on Sunday, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merrimack Pharmaceuticals earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.

Who are some of Merrimack Pharmaceuticals' key competitors?

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the folowing people:
  • Dr. Richard Peters, Pres, CEO & Director (Age 55)
  • Ms. Jean M. Franchi, CFO & Treasurer (Age 52)
  • Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 41)
  • Dr. Daryl C. Drummond Ph.D., Head of Research (Age 49)
  • Dr. Sergio L. Santillana, Chief Medical Officer (Age 55)

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (4.30%), Rubric Capital Management LP (4.16%), Clearline Capital LP (2.41%), JPMorgan Chase & Co. (0.41%), JPMorgan Chase & Co. (0.41%) and Stonebridge Capital Management Inc. (0.26%). Company insiders that own Merrimack Pharmaceuticals stock include Daryl C Drummond and Ulrik B Nielsen. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

Which major investors are buying Merrimack Pharmaceuticals stock?

MACK stock was purchased by a variety of institutional investors in the last quarter, including Clearline Capital LP, Dimensional Fund Advisors LP, Rubric Capital Management LP, JPMorgan Chase & Co., JPMorgan Chase & Co. and Stonebridge Capital Management Inc.. View Insider Buying and Selling for Merrimack Pharmaceuticals.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $4.52.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $60.31 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $472.02 million in net income (profit) each year or ($5.66) on an earnings per share basis. Merrimack Pharmaceuticals employs 72 workers across the globe.

What is Merrimack Pharmaceuticals' official website?

The official website for Merrimack Pharmaceuticals is http://www.merrimackpharma.com.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]


MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  313 (Vote Outperform)
Underperform Votes:  242 (Vote Underperform)
Total Votes:  555
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel